Skip to content

Study · Not a test of the peptide alone · 2026

1 result

NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development.

Zeng K, Zhu Y, Han Z, Xiong S, Zhao Y, Xiao Z, Xie Y, Jin S, Dong T, Lan L, Liu W, Du Y, Guan C, Yu X, Song X

Cell death and differentiation11 Sept 2025Cited by 4 (Europe PMC)

PMID40935835 (opens in a new tab)DOI10.1038/s41418-025-01578-5 (opens in a new tab)PepBankPUB-40935835
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking KPV.

  1. 01AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome

    In a mouse model of vitiligo, KPV-modified liposomes carrying Nlrp3 shRNA alleviated vitiligo development; KPV served as the targeting ligand.

    In plain wordsIn mice with vitiligo, liposomes that use KPV as a targeting tag and carry Nlrp3 shRNA reduced vitiligo development.

    Peptide
    KPV
    Outcome
    DecreaseVitiligo development
    Study

    mousen: not reported in source

    Melanoma-Treg-induced vitiligo mouse model
    Outcome group
    Pigmentation · Skin and wound

    Source sentences

    Summary
    Notably, melanocyte-specific knockdown of NLRP3 using lysine-proline-valine (KPV)-modified deformable liposomes (KPV-Lipos) carrying Nlrp3 shRNA significantly alleviates vitiligo development.
    1 context sentence
    Summary · context
    melanoma-Treg-induced vitiligo mouse model.

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.